Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the
adoption of AI to advance precision medicine and patient care,
today announced a collaboration with Genialis, the RNA-biomarker
company. The multi-year agreement allows Genialis to leverage
Tempus’ multimodal dataset to develop new RNA-based algorithms
across cancer types.
Clinical care for cancer patients is hindered by insufficient
biomarkers that fail to accurately predict patient response to
treatment. To address this, Genialis has developed an AI foundation
model using data from ~1 million RNA-sequencing samples
representing globally diverse patients. This large molecular model
(LMM), dubbed the Genialis TM Supermodel, yields accurate and
information-rich biomarker algorithms to help biopharma improve
therapeutic development. Validating Genialis’ LMM using Tempus
real-world multi-modal data is essential to demonstrate the
clinical utility and broad applicability of these biomarkers in
drug development and clinical practice. As part of the
collaboration, Genialis can now leverage Tempus’ analytics
platform, Lens, which provides a development platform accessing
de-identified multimodal patient records and a suite of tools to
validate signatures to accelerate the company’s efforts to bring
its clinical algorithms to market. In return, Tempus gains the
right to evaluate and potentially license Genialis-developed
algorithms for commercialization as a component of the xR
platform.
Tempus multimodal dataset has already proved pivotal in the
launch of Genialis™krasID, the first commercially available
algorithm that stratifies patients who benefit from KRAS
inhibition. Presented at the 6th Annual Targeting-RAS Drug
Development Summit in September 2024, Genialis krasID uniquely
predicts patient response to KRAS-targeted therapies across cancer
types and driver mutations. Independently validated using Tempus’
real-world data, Genialis krasID stratifies patients into high and
low likelihood response groups that have been evaluated in
real-world studies1,2.
“We look forward to working with Genialis and demonstrating new
ways in which our data can be applied to further a new kind of
research, one that embraces the power that RNA-based biomarkers can
have on the future of cancer care,” said Kate Sasser, Ph.D., Chief
Scientific Officer at Tempus. “Multimodal algorithms, including RNA
signatures, are demonstrating rapid advancement in clinical utility
for personalized treatment decisions, and we are excited to partner
with Genialis to fuel this data-driven precision medicine future
with our xR assay and vast multimodal dataset.”
“Biomarkers have the potential to transform how cancer is
diagnosed and treated, but today’s standard of care leaves a lot to
be desired in terms of accuracy, information richness, and patient
reach,” said Rafael Rosengarten, Ph.D., CEO of Genialis. “With this
strategic agreement with Tempus, Genialis will have access to an
unparalleled data resource to validate our cutting-edge patient
classifiers.”
About Tempus
Tempus is a technology company advancing precision medicine
through the practical application of artificial intelligence in
healthcare. With one of the world’s largest libraries of multimodal
data, and an operating system to make that data accessible and
useful, Tempus provides AI-enabled precision medicine solutions to
physicians to deliver personalized patient care and in parallel
facilitates discovery, development and delivery of optimal
therapeutics. The goal is for each patient to benefit from the
treatment of others who came before by providing physicians with
tools that learn as the company gathers more data. For more
information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended (the “Securities Act”), and Section 21E of the Securities
Exchange Act of 1934, as amended, about Tempus and Tempus’ industry
that involve substantial risks and uncertainties. All statements
other than statements of historical facts contained in this press
release are forward-looking statements, including, but not limited
to, statements regarding the expected outcomes and benefits of the
collaboration with Genialis in developing biomarker algorithms, are
forward-looking statements. In some cases, you can identify
forward-looking statements because they contain words such as
“anticipate,” “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “going to,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” or the negative of these words or other similar terms or
expressions. Tempus cautions you that the foregoing may not include
all of the forward-looking statements made in this press
release.
You should not rely on forward-looking statements as predictions
of future events. Tempus has based the forward-looking statements
contained in this press release primarily on its current
expectations and projections about future events and trends that it
believes may affect Tempus’ business, financial condition, results
of operations and prospects. These forward-looking statements are
subject to risks and uncertainties related to: Tempus’ financial
performance; the ability to attract and retain customers and
partners; managing Tempus’ growth and future expenses; competition
and new market entrants; compliance with new laws, regulations and
executive actions, including any evolving regulations in the
artificial intelligence space; the ability to maintain, protect and
enhance Tempus’ intellectual property; the ability to attract and
retain qualified team members and key personnel; the ability to
repay or refinance outstanding debt, or to access additional
financing; future acquisitions, divestitures or investments; the
potential adverse impact of climate change, natural disasters,
health epidemics, macroeconomic conditions, and war or other armed
conflict, as well as risks, uncertainties, and other factors
described in the section titled “Risk Factors” in Tempus’ Quarterly
Report on Form 10-Q for the quarter ended September 30, 2024 filed
with the Securities and Exchange Commission (“SEC”) as well as in
other filings Tempus may make with the SEC in the future. In
addition, any forward-looking statements contained in this press
release are based on assumptions that Tempus believes to be
reasonable as of this date. Tempus undertakes no obligation to
update any forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
About Genialis
Genialis, the RNA biomarker company, is creating a world where
healthcare delivers the best possible outcomes for patients, their
families, and their communities. Genialis develops and validates
clinically actionable biomarkers informed by the world’s most
ethnographically diverse cancer data sets to better predict patient
responses and guide treatment decisions for targeted inhibitors,
immunotherapies, and other emerging therapeutic classes. Genialis
is trusted by pharma and diagnostics partners, and together, we are
transforming medicine through data. For more information, please
visit www.genialis.com
1 Žiberna, et al. (2024). Genialis™ krasID: Biology-Driven
Machine Learning to Personalize KRAS Inhibitor Therapy. Presented
at the American Association for Cancer Research (AACR) Annual
Meeting. Retrieved from
https://www.genialis.com/2024/04/09/genialis-krasid-biology-driven-machine-learning-to-personalize-kras-inhibitor-therapy/
2 Žiberna, et al. (2024). krasID at RAS Drug Development Summit.
Poster presented at the RAS Drug Development Summit, American
Association for Cancer Research (AACR). Retrieved from
https://www.genialis.com/2024/09/25/genialis-krasid-biology-driven-machine-learning-to-personalize-kras-inhibitor-therapy-2/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250108867515/en/
Erin Carron media@tempus.com
Tempus AI (NASDAQ:TEM)
過去 株価チャート
から 12 2024 まで 1 2025
Tempus AI (NASDAQ:TEM)
過去 株価チャート
から 1 2024 まで 1 2025
